

# Philip B Miner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7622025/publications.pdf>

Version: 2024-02-01

17  
papers

876  
citations

1039406

9  
h-index

996533

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

662  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastric Acid Control With Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole: A Five-Way Crossover Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 2616-2620.	0.2	371
2	Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. <i>American Journal of Gastroenterology</i> , 2002, 97, 1332-1339.	0.2	143
3	A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2017, 112, 613-621.	0.2	117
4	Effect of Tegaserod on Esophageal Pain Threshold, Regurgitation, and Symptom Relief in Patients With Functional Heartburn and Mechanical Sensitivity. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 442-450.	2.4	69
5	Esophageal Visceral Sensitivity to Bile Salts in Patients with Functional Heartburn and in Healthy Control Subjects. <i>Digestive Diseases and Sciences</i> , 2005, 50, 81-85.	1.1	68
6	Evaluation of anorectal physiology in patients with increased mast cells. <i>Digestive Diseases and Sciences</i> , 1993, 38, 877-881.	1.1	29
7	Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C). <i>American Journal of Gastroenterology</i> , 2014, 109, S541.	0.2	25
8	Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. <i>BMC Gastroenterology</i> , 2014, 14, 188.	0.8	15
9	Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1381-1388.	0.9	13
10	Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 177-183.	0.9	9
11	Plecanatide for the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 71-84.	1.4	8
12	Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation. <i>Drug Safety</i> , 2019, 42, 603-615.	1.4	4
13	Exploring the physiologic role of human gastroesophageal reflux by analyzing time-series data from 24-h gastric and esophageal pH recordings. <i>Physiological Reports</i> , 2014, 2, e12051.	0.7	3
14	Pheasant-induced dysphagia. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1743-1746.	1.1	1
15	Evaluation of Esophageal Sensation. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2014, 24, 619-632.	0.6	1
16	Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment. <i>Advances in Therapy</i> , 2018, 35, 2024-2040.	1.3	0
17	Effect of Treatment on the Risk of Viral Infections in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1648-1649.	2.4	0